Universität zu Köln

Lehmann, C., Malin, J., Suarez, I. and Faetkenheuer, G. (2019). Modern HIV treatment. Internist, 60 (4). S. 411 - 420. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1432-1289

Full text not available from this repository.

Abstract

Human immunodeficiency virus (HIV) infection has become achronic disease with afavourable prognosis if adequate antiretroviral therapy (ART) is applied. Therefore, each patient with HIV infection should be treated irrespectively of clinical symptoms or of immunological status. Acombination of three active drugs that have to be taken life-long has been standard for many years. The regimen contains two nucleoside reverse transcriptase inhibitors plus either an integrase inhibitor, aboosted protease inhibitor, or anon-nucleoside reverse transcriptase inhibitor. Integrase inhibitors are recommended as the third partner of choice by recent guidelines due to their high efficacy and their favourable safety profile. Many combination drugs are now available which allow asimple treatment with few tablets and in many instances aone-pill combination per day is an option. Potential interactions with drugs given for other diseases have to be taken into account, especially if apharmacological booster is part of the regimen. Combination therapy should be changed if either virological failure (HIV RNA >200 copies/ml) or drug-related adverse events occur. In special situations (e.g. pregnancy) highly experienced experts in the field should be consulted. Novel approaches for HIV therapy include dual therapy as well as treatment with long-acting substances. Beside therapy, antiretroviral drugs are used for prevention either as post-exposure prophylaxis or as pre-exposure prophylaxis.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Lehmann, C. UNSPECIFIED UNSPECIFIED UNSPECIFIED Malin, J. UNSPECIFIED UNSPECIFIED UNSPECIFIED Suarez, I. UNSPECIFIED UNSPECIFIED UNSPECIFIED Faetkenheuer, G. UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-152274
DOI:	10.1007/s00108-019-0564-0
Journal or Publication Title:	Internist
Volume:	60
Number:	4
Page Range:	S. 411 - 420
Date:	2019
Publisher:	SPRINGER HEIDELBERG
Place of Publication:	HEIDELBERG
ISSN:	1432-1289
Language:	German
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language PREEXPOSURE PROPHYLAXIS; ADULTS; DOLUTEGRAVIR; INFECTION; EMTRICITABINE; RILPIVIRINE; LAMIVUDINE; EFFICACY; ABACAVIR; PHASE-3 Multiple languages Medicine, General & Internal Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/15227